Pfizer Inc., New York, NY, USA.
Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x.
Drug-drug interactions with warfarin are common with potentially harmful consequences. Preclinical in vitro studies suggest that fesoterodine or 5-hydroxymethyl tolterodine are not likely to affect warfarin metabolism, but a lack of interaction has not been demonstrated in a clinical study.
This study shows that the pharmacokinetics and pharmacodynamics of warfarin 25 mg in healthy adults are unaffected by fesoterodine 8 mg, and that co-administration of warfarin 25 mg and fesoterodine 8 mg is safe and well tolerated.
To confirm the lack of an interaction of fesoterodine 8 mg with warfarin pharmacokinetics and pharmacodynamics in healthy adults.
In this open-label, two-treatment, crossover study, subjects (n= 14) aged 20-41 years with normal prothrombin time (PT) and International Normalized Ratio (INR) were randomized to receive a single dose of warfarin 25 mg alone in one period and fesoterodine 8 mg once daily on days 1-9 with a single dose of warfarin 25 mg co-administered on day 3 in the other period. There was a 10-day washout between treatments. Pharmacokinetic endpoints were area under the plasma concentration-time curve from time 0 to infinity (AUC(0,∞)), maximum plasma concentration (C(max)), AUC from time 0 to the time of the last quantifiable concentration (AUC(0,last)), time to C(max) (t(max) ), and half-life (t(1/2)) for S- and R-warfarin. Pharmacodynamic endpoints were area under the INR-time curve (AUC(INR) ), maximum INR (INR(max)), area under the PT-time curve (AUC(PT)) and maximum PT (PT(max)).
Across all pharmacokinetic and pharmacodynamic comparisons, the point estimates of treatment ratio (warfarin co-administered with fesoterodine vs. warfarin alone) were 92-100%. The 90% confidence intervals for the ratios of the adjusted geometric means were contained within (80%, 125%). There were no clinically relevant changes in laboratory tests, vital signs or ECG recordings.
The pharmacokinetics and pharmacodynamics of warfarin 25 mg in healthy adults are unaffected by fesoterodine 8 mg. Concomitant administration of fesoterodine and warfarin was well tolerated.
华法林与药物相互作用很常见,可能具有潜在的有害后果。临床前体外研究表明,非索罗定或 5-羟甲基托特罗定不太可能影响华法林的代谢,但在临床研究中尚未证明存在相互作用。
本研究表明,健康成年人服用 25 毫克华法林时,非索罗定 8 毫克不会影响华法林的药代动力学和药效学,并且同时服用 25 毫克华法林和非索罗定是安全且耐受良好的。
确认非索罗定 8 毫克与健康成年人华法林药代动力学和药效学无相互作用。
在这项开放标签、两治疗、交叉研究中,年龄在 20-41 岁之间、凝血酶原时间(PT)和国际标准化比值(INR)正常的受试者(n=14)被随机分为两组,一组在一个周期内单独服用 25 毫克华法林,另一组在一个周期内每天服用 8 毫克非索罗定,连续服用 9 天,在第 3 天同时服用 25 毫克华法林。两种治疗方案之间有 10 天的洗脱期。药代动力学终点为从 0 到无穷大的血浆浓度-时间曲线下面积(AUC(0,∞))、最大血浆浓度(C(max))、从 0 到最后可定量浓度的时间的 AUC(AUC(0,last))、C(max)时间(t(max))和 S-和 R-华法林的半衰期(t(1/2))。药效学终点为 INR-时间曲线下面积(AUC(INR))、最大 INR(INR(max))、PT-时间曲线下面积(AUC(PT))和最大 PT(PT(max))。
在所有药代动力学和药效学比较中,治疗比值(与非索罗定合用的华法林与单独使用的华法林)的点估计值为 92-100%。比值的 90%置信区间包含在(80%,125%)内。实验室检查、生命体征或心电图记录均无临床相关变化。
健康成年人服用 25 毫克华法林时,非索罗定 8 毫克不会影响华法林的药代动力学和药效学。同时服用非索罗定和华法林耐受性良好。